齐默巴奥米特控股（Zimmer Biomet）今日盘前股价大涨5.55%，引起市场广泛关注。这一显著涨幅主要得益于公司发布的强劲第二季度财报以及上调的全年业绩指引。
根据公司公布的财报，齐默巴奥米特控股第二季度调整后每股收益达2.07美元，显著超出分析师预期的1.98美元。季度销售额为20.8亿美元，同样高于市场预期的20.5亿美元。值得注意的是，公司运动医学和创伤护理产品部门表现尤为出色，销售额同比增长17.3%，达到5.51亿美元，超过分析师预计的5.34亿美元。
齐默巴奥米特控股股价大涨的另一个重要因素是公司上调了全年业绩指引。公司现预计2025年全年调整后每股收益将达到8.1-8.3美元，高于此前预期的7.9-8.1美元。同时，公司将2025年收入增长率预期上调至6.7%至7.7%。这一乐观展望反映了医疗器械市场需求强劲，特别是在髋关节和膝关节植入物方面。公司首席执行官Ivan Tornos表示，强劲的新产品周期推动了美国髋关节和膝关节产品组合的大幅增长，同时也带动了全球运动医学、四肢和创伤业务的持续强劲增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.